Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
AJ Cooper, LV Sequist, JJ Lin - Nature Reviews Clinical Oncology, 2022 - nature.com
The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …
[HTML][HTML] Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
YL Wu, R Dziadziuszko, JS Ahn, F Barlesi… - … England Journal of …, 2024 - Mass Medical Soc
Background Platinum-based chemotherapy is the recommended adjuvant treatment for
patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC). Data on the …
patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC). Data on the …
[HTML][HTML] Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working …
Next-generation sequencing (NGS) allows sequencing of a high number of nucleotides in a
short time frame at an affordable cost. While this technology has been widely implemented …
short time frame at an affordable cost. While this technology has been widely implemented …
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in …
Q Zhou, M Chen, O Jiang, Y Pan, D Hu, Q Lin… - The Lancet …, 2022 - thelancet.com
Background A substantial proportion of patients with unresectable stage III non-small-cell
lung cancer (NSCLC) cannot either tolerate or access concurrent chemoradiotherapy, so …
lung cancer (NSCLC) cannot either tolerate or access concurrent chemoradiotherapy, so …
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …
Association of patient characteristics and tumor genomics with clinical outcomes among patients with non–small cell lung cancer using a clinicogenomic database
Importance Data sets linking comprehensive genomic profiling (CGP) to clinical outcomes
may accelerate precision medicine. Objective To assess whether a database that combines …
may accelerate precision medicine. Objective To assess whether a database that combines …
[HTML][HTML] ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
Highlights•A virtual consensus on the management of EGFR-mutant NSCLC was organized
by the ESMO, including 34 experts from 18 countries.•The experts compiled …
by the ESMO, including 34 experts from 18 countries.•The experts compiled …
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
D Planchard, EF Smit, HJM Groen, J Mazieres… - The Lancet …, 2017 - thelancet.com
Summary Background BRAF V600E mutation occurs in 1–2% of lung adenocarcinomas and
acts as an oncogenic driver. Dabrafenib, alone or combined with trametinib, has shown …
acts as an oncogenic driver. Dabrafenib, alone or combined with trametinib, has shown …
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S Novello, F Barlesi, R Califano, T Cufer… - Annals of …, 2016 - annalsofoncology.org
Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …